“A Knockout Punch for Early HER2 Breast Cancer”

HER2 positive breast cancers responded to Taxol and Herceptin

(dailyRx News) About one in five women diagnosed with breast cancer have too much of a protein called HER2, which makes the cancer more likely to grow faster and return. New research has some good news for women with this cancer.

In a phase ll trial, all but a few women with HER-2 positive breast cancer were disease-free more than three years after receiving mild chemotherapy and the targeted therapy, Herceptin (trastuzumab).

The authors of this study suggested these findings should be regarded as a new standard of care for treating small HER2-positive breast cancers.

Read more from RxWiki HERE.

Tags:

Proud Members of